Patients Undergoing Pancreatic Surgery at the Antwerp University Hospital. (PANREG)

February 26, 2026 updated by: University Hospital, Antwerp

Pancreatic Surgery Registry (PANREG)

There is a need for a structured registry to collect real-world data on patient characteristics, surgical strategies, perioperative outcomes, and long-term results. Such a registry will provide insights into quality of care, support benchmarking, and form the basis for clinical and translational research.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

The objective of this study is to collect and register all clinical data on patients undergoing pancreatic surgery at Antwerp University Hospital. Data collection will include demographic information, medical history, preoperative workup, surgical details, postoperative outcomes, lab results, pathology results and long-term follow-up.

There is no intervention in this study; patient care will be done according to the current standard of care. The data will be used to further improve patient outcomes, identify risk factors for complications (both patient-specific and procedure-specific), investigate oncological outcomes and long-term patient survival, help predict exocrine and endocrine insufficiency, and identify patient populations in which specific screening for this is indicated.

Study Type

Observational

Enrollment (Estimated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
    • Antwerp
      • Edegem, Antwerp, Belgium, 2650
        • University Hospital Antwerp

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing pancreatic surgery

Description

Inclusion Criteria:

  • benign indications for pancreatic surgery, including chronic pancreatitis, cystic lesions and IPMN
  • malignant indications for pancreatic surgery, including PDAC, duodenal carcinoma, pancreatic neuro-endocrine tumours, distal cholangiocarcinoma.

Exclusion criteria:

  • indications for pancreatic resection caused by acute pancreatitis
  • pancreatic resection after abdominal trauma

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
90-day mortality
Time Frame: 25 years
90-day mortality
25 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Establishment of a registry for patients undergoing pancreatic surgery - secondary outcome measures
Time Frame: 25 years
  • 30-day mortality
  • morbidity, expressed as specific postpancreatectomy complications ( = defined by the ISPGS (International Study Group for Pancreatic Surgery), i.e. POPF (postoperative pancreatic fistula), chyle leak, PPH (postpancreatectomy haemorrhage), bile leak and delayed gastric emptying), postoperative complications defined by the Clavien Dindo scoring and the CCI (comprehensive complication index)
  • duration of hospital stay
  • need for postoperative transfusion
  • development of exocrine- or endocrine insufficiency (through systematic postoperative function testing)
  • overall survival
  • disease free survival
25 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Antwerp

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 19, 2025

Primary Completion (Estimated)

January 1, 2050

Study Completion (Estimated)

January 1, 2050

Study Registration Dates

First Submitted

January 15, 2026

First Submitted That Met QC Criteria

February 26, 2026

First Posted (Actual)

March 2, 2026

Study Record Updates

Last Update Posted (Actual)

March 2, 2026

Last Update Submitted That Met QC Criteria

February 26, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 004516

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Full access to the dataset will be limited to the PI, co-PI and study coordinator.

Site investigators may access the full dataset upon formal request, subject to approval by the steering group. Requests must include a description of their research plans for consideration.

IPD Sharing Time Frame

IPD would be available depending on the study...

IPD Sharing Access Criteria

Full access to the dataset will be limited to the PI, co-PI and study coordinator.

Site investigators may access the full dataset upon formal request, subject to approval by the steering group. Requests must include a description of their research plans for consideration.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malignant Pancreatic Neoplasm

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe